Exasol’s High-Performance Database Now Available as SaaS Model
Exasol has today announced that its high-performance analytics database is now available through a software-as-a-service (SaaS) model on Amazon Web Services (AWS). Exasol’s SaaS offering, initially available in two versions, provides businesses the high performance and ease of use that Exasol is known for without them having to manage their own hardware infrastructure. Exasol, named Technology Partner of the Year 2021 in DACH by AWS, worked extensively with AWS SaaS Factory to deliver its SaaS model.
“As a company focused completely on superior analytics performance, we want to be able to provide businesses the same impressive experience wherever their data goes. It’s exactly for this reason that we are building a bridge for organizations to be able to move analytics processes to the cloud without risk, without friction, and without taking performance hits - something that Exasol is uniquely placed to offer,” said Mathias Golombek, CTO of Exasol. “As part of this, AWS gives us the ideal platform to build out our SaaS solution. It allows us to separate the compute from the storage, meaning we can elastically scale up and down compute power to optimize the costs and workloads for our customers.”
Exasol’s deep technical partnership with AWS has been key to ensure it can deliver the best-in-class performance via its SaaS offering. For Exasol, as an in-memory database, the ability to seamlessly increase or decrease its memory footprint is important. The AWS cloud platform provides Exasol with the ability to scale both vertically and horizontally to meet its needs. Furthermore, as Exasol seamlessly manages hot and cold data between the object store, local SSDs and main memory, AWS provides Exasol with the infrastructure to do that without compromising performance.
“We understand the immense challenges facing companies in terms of extracting value from data to drive their business. We believe that companies who master this discipline will be better equipped for long-term success. Performance and cost are key drivers of any successful data strategy, and we are extremely proud to now offer our world-class performance technology through a consumption-based SaaS model on AWS for customers looking to move away from slow and costly systems without disruption to their business,” said Aaron Auld, CEO of Exasol. “Our technology is perfectly suited to solving the challenges that come with implementing cloud-first strategies while minimizing risk. Exasol’s SaaS offering is a key step towards delivering best-in-class performance combined with immediate budget relief to our customers.”
With Exasol’s SaaS offering, customers can be up and running in a matter of minutes, in a fully managed system, while still benefiting from the best-in-class high-performance database technology that Exasol is known for without compromising security. When deployed in a public cloud, Exasol leverages native security measures such as AWS IAM or Active Directory services, as well as built-in security features. For customers who prefer to manage their own cloud solution, Exasol can also run on their cloud of choice, and for those looking for the ultimate control over their data, customers can continue to run Exasol on-premises. A hybrid solution is also possible for those customers who have needs that span several environments. Exasol is working to deliver a model which allows customers to select the appropriate deployment for different workloads, depending on regulatory considerations and their business needs. The launch of the SaaS model is the next step in this direction.
Andy Hayler, CEO of the Information Difference commented on the announcement: “Whilst cloud computing is a foundation for many businesses, especially digital ones, most organizations are yet to move fully to the cloud. Exasol is providing customers the best of both worlds with its SaaS offering, offering them freedom to undertake a hybrid cloud strategy and migrate at their own pace. By not focusing on a 'cloud-only' approach to its solutions Exasol enables customers to derive business value from their data quickly, easily and cost effectively, no matter where they choose to store their data, based on a high performance, flexible and scalable platform.”
About Exasol
Exasol was founded in 2000 with the vision to transform how organizations use data. Today, Exasol’s analytics database – the fastest in the world – is trusted by the world’s most ambitious organizations. With offices in several locations across the US and Europe, Exasol is committed to delivering flexible, scalable and powerful analytics solutions to customers wherever they are, in the cloud – public or private - or on-premises.
Exasol – accelerating insights from the world’s data.
Learn more at: www.exasol.com and follow us on social media: LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220203005141/en/
Contact information
PR:
Isabella Alder, EMEA Communications Manager at Exasol
Email:
isabella.alder@exasol.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 05:12:00 EEST | Press release
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results. This press release features multimedia. View the full release here: https://www.businesswire.
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 05:00:00 EEST | Press release
Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese market by optimizing their website UI/UX, thereby enhancing the effectiveness of their Google Ads campaigns. Background of the Partnership Known as a "Start-up Nation," Israel is home to many
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 04:11:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14th edition of Nat
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 115.5.2025 00:03:00 EEST | Press release
Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo through eight weeks of treatment. NT1 is a severe, chronic neurological condition caused by a significant loss of orexin-producing neurons, resulting in low levels of orexin leading to EDS, cataplexy (sudden loss of muscle tone), cognitive symptoms, disrupted nighttime sleep, hallucinations that occur as one falls asleep or wakes up and sleep paralysis.T
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 23:05:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation science and patient-focused innovation. “With three cornerstone hematology assets – BRUKINSA, sonrotoclax and BGB-16673 – we are advancing a potentially best-in-class portfolio in B-cell malignancies,” said Lai Wang, Ph.D. Global Head of R&D. “At EHA 2025, we’ll share 31 accepted ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom